Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | ESRRA | P11474 | 2/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498016 | 0.78 | MCHR1 (0.43) | ALDH1A1MAPT | |
| SCHEMBL890168 | 0.75 | F2 (0.52) | COMTNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL12362761 | 0.74 | ESR1 (0.44) | ESR1ESR2ESRRAMIFCAPN1 | |
| SCHEMBL3989146 | 0.74 | IDH1 (0.44) | ESR1ESR2ESRRAMAPT | |
| SCHEMBL3987287 | 0.74 | AKR1B1 (0.51) | — | |
| SCHEMBL12386351 | 0.71 | ESR1 (0.44) | ESR1ESR2ESRRAMIFNPC1 | |
| SCHEMBL1753473 | 0.70 | ALDH1A1 (0.41) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL18011087 | 0.70 | ALDH1A1 (0.53) | COMTNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL130630 | 0.70 | — | — | |
| SCHEMBL2189031 | 0.70 | POLB (0.51) | ESR1ESR2ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | ESR1 1513/4885ESR2 1468/4885ESRRA 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.